APA (7th ed.) Citation

D, J., AJ, R., J, A., S, F., L, T., S, P., . . . AD, D. (2022). Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: An open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. The Lancet. Microbe, 3(9), e663. https://doi.org/10.1016/S2666-5247(22)00126-4

Chicago Style (17th ed.) Citation

D, Jenkin, et al. "Safety and Immunogenicity of a Simian-adenovirus-vectored Rabies Vaccine: An Open-label, Non-randomised, Dose-escalation, First-in-human, Single-centre, Phase 1 Clinical Trial." The Lancet. Microbe 3, no. 9 (2022): e663. https://doi.org/10.1016/S2666-5247(22)00126-4.

MLA (9th ed.) Citation

D, Jenkin, et al. "Safety and Immunogenicity of a Simian-adenovirus-vectored Rabies Vaccine: An Open-label, Non-randomised, Dose-escalation, First-in-human, Single-centre, Phase 1 Clinical Trial." The Lancet. Microbe, vol. 3, no. 9, 2022, p. e663, https://doi.org/10.1016/S2666-5247(22)00126-4.